MA27539A1 - Nouvelle combinaison synergique contenant du roflumilast et du formoterol - Google Patents

Nouvelle combinaison synergique contenant du roflumilast et du formoterol

Info

Publication number
MA27539A1
MA27539A1 MA28343A MA28343A MA27539A1 MA 27539 A1 MA27539 A1 MA 27539A1 MA 28343 A MA28343 A MA 28343A MA 28343 A MA28343 A MA 28343A MA 27539 A1 MA27539 A1 MA 27539A1
Authority
MA
Morocco
Prior art keywords
formoterol
synergistic combination
combination containing
new synergistic
containing roflumilast
Prior art date
Application number
MA28343A
Other languages
English (en)
French (fr)
Inventor
Rolf Beume
Daniela Bundschuh
Norbert Kolassa
Degenhard Marx
Christian Weimar
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of MA27539A1 publication Critical patent/MA27539A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA28343A 2002-11-27 2005-06-16 Nouvelle combinaison synergique contenant du roflumilast et du formoterol MA27539A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27

Publications (1)

Publication Number Publication Date
MA27539A1 true MA27539A1 (fr) 2005-09-01

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28343A MA27539A1 (fr) 2002-11-27 2005-06-16 Nouvelle combinaison synergique contenant du roflumilast et du formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (enExample)
EP (1) EP1567139B1 (enExample)
JP (1) JP2006508994A (enExample)
KR (1) KR101071798B1 (enExample)
CN (1) CN100346777C (enExample)
AT (1) ATE399543T1 (enExample)
AU (1) AU2003292120B2 (enExample)
BR (1) BR0316451A (enExample)
CA (1) CA2506962C (enExample)
CO (1) CO5690570A2 (enExample)
CY (1) CY1110369T1 (enExample)
DE (1) DE60321953D1 (enExample)
DK (1) DK1567139T3 (enExample)
EA (1) EA009935B1 (enExample)
ES (1) ES2309357T3 (enExample)
HR (1) HRP20050579B1 (enExample)
IL (1) IL168308A (enExample)
IS (1) IS2575B (enExample)
MA (1) MA27539A1 (enExample)
ME (1) ME00489B (enExample)
MX (1) MXPA05005437A (enExample)
NO (1) NO334247B1 (enExample)
NZ (1) NZ540659A (enExample)
PL (1) PL216752B1 (enExample)
PT (1) PT1567139E (enExample)
RS (1) RS51081B (enExample)
SI (1) SI1567139T1 (enExample)
TN (1) TNSN05131A1 (enExample)
UA (1) UA83018C2 (enExample)
WO (1) WO2004047829A1 (enExample)
ZA (1) ZA200503308B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PL1606261T3 (pl) 2003-03-10 2010-04-30 Astrazeneca Ab Nowy sposób przygotowania roflumilastu
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
EP2359826B1 (en) * 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
WO2014115127A1 (en) 2013-01-28 2014-07-31 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
BR9807399B1 (pt) * 1997-02-17 2011-04-19 composição para o tratamento de sìndrome da angústia respiratória infantil (irds) ou sìndrome da angústia respiratória aguda (ards) compreendendo 3-(ciclopropilmetóxi)-n-(3,5-dicloro-4-piridinil)-4-(difl uorometóxi) benzamida e tensoativo do pulmão, e seu uso.
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
US6333354B1 (en) * 1997-02-28 2001-12-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
NZ527232A (en) * 1998-08-26 2005-03-24 Smithkline Beecham Corp A composition contaning a PDE 4 inhibitor and a beta adrenergic bronchodilator useful for treating pulmonary diseases
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
EP1671651B1 (en) * 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP4143413B2 (ja) * 2001-03-22 2008-09-03 グラクソ グループ リミテッド β2−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
ATE411334T1 (de) * 2001-04-30 2008-10-15 Glaxo Group Ltd Antiphlogistische 7.beta.-carbothioate esterderivate von androstan mit einer 17.alpha.- zyklischen estergruppe

Also Published As

Publication number Publication date
DK1567139T3 (da) 2008-11-03
MXPA05005437A (es) 2005-08-03
EA200500774A1 (ru) 2005-12-29
IL168308A (en) 2010-12-30
WO2004047829A1 (en) 2004-06-10
PT1567139E (pt) 2008-10-01
NO334247B1 (no) 2014-01-20
CN100346777C (zh) 2007-11-07
KR20050085104A (ko) 2005-08-29
CA2506962A1 (en) 2004-06-10
KR101071798B1 (ko) 2011-10-11
CY1110369T1 (el) 2015-04-29
JP2006508994A (ja) 2006-03-16
AU2003292120A1 (en) 2004-06-18
ES2309357T3 (es) 2008-12-16
HRP20050579A2 (hr) 2006-04-30
EA009935B1 (ru) 2008-04-28
CA2506962C (en) 2012-01-03
IS2575B (is) 2010-02-15
UA83018C2 (uk) 2008-06-10
ME00489B (me) 2011-10-10
NO20052999L (no) 2005-06-17
CO5690570A2 (es) 2006-10-31
BR0316451A (pt) 2005-10-11
HRP20050579B1 (hr) 2014-01-31
ZA200503308B (en) 2006-11-29
CN1713903A (zh) 2005-12-28
EP1567139B1 (en) 2008-07-02
HK1081861A1 (en) 2006-05-26
PL216752B1 (pl) 2014-05-30
AU2003292120B2 (en) 2010-01-21
DE60321953D1 (de) 2008-08-14
US20060142308A1 (en) 2006-06-29
IS7898A (is) 2005-06-20
TNSN05131A1 (en) 2007-05-14
SI1567139T1 (sl) 2008-12-31
EP1567139A1 (en) 2005-08-31
RS51081B (sr) 2010-10-31
RS20050382A (sr) 2007-08-03
WO2004047829A8 (en) 2005-06-30
ATE399543T1 (de) 2008-07-15
PL377732A1 (pl) 2006-02-06
NZ540659A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
DE60026855D1 (de) Synergistische kombination von roflumilast und salmeterol
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0012362D0 (en) Chemical compounds
DE69901936D1 (de) Nasale lösungen
MXPA05009986A (es) Tratamiento de la enfermedad de alzheimer.
MA27539A1 (fr) Nouvelle combinaison synergique contenant du roflumilast et du formoterol
SE0102055D0 (sv) New Compounds
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
BR9915123A (pt) Composição de uma substância farmaceuticamente ativa e dispensador
MXPA04002560A (es) Combinacion de un nsaid y un inhibidor pde-4.
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
EA200500865A1 (ru) Синергетическая комбинация, включающая рофлумиласт и r,r-формотерол
MA28266A1 (fr) Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles bipolaires
MD2875F1 (en) Remedy for nasal congestion treatment
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa
TNSN01081A1 (fr) Compositions de s-methyl-dihydro-ziprasidone
MA27291A1 (fr) Acides phenoxyacetiques substitues